134 related articles for article (PubMed ID: 22498987)
1. Treatment and management of chronic lymphocytic leukemia in the elderly: what the pharmacist clinician should know.
Johnson TM
Consult Pharm; 2012 Apr; 27(4):274-85. PubMed ID: 22498987
[TBL] [Abstract][Full Text] [Related]
2. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
3. A review of pharmacologic options for previously untreated chronic lymphocytic leukemia.
Wilhelm K; Yang D
J Oncol Pharm Pract; 2011 Jun; 17(2):91-103. PubMed ID: 20085962
[TBL] [Abstract][Full Text] [Related]
4. Chronic lymphocytic leukemia in the elderly population.
Rai KR
Clin Geriatr Med; 1997 May; 13(2):245-9. PubMed ID: 9115449
[TBL] [Abstract][Full Text] [Related]
5. Revision of the guidelines for diagnosis and therapy of chronic lymphocytic leukemia (CLL).
Eichhorst B; Hallek M
Best Pract Res Clin Haematol; 2007 Sep; 20(3):469-77. PubMed ID: 17707834
[TBL] [Abstract][Full Text] [Related]
6. A review of heart failure management in the elderly population.
Cheng JW; Nayar M
Am J Geriatr Pharmacother; 2009 Oct; 7(5):233-49. PubMed ID: 19948300
[TBL] [Abstract][Full Text] [Related]
7. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
8. Bendamustine: a new treatment option for chronic lymphocytic leukemia.
Glode AE; Jarkowski A
Pharmacotherapy; 2009 Nov; 29(11):1375-84. PubMed ID: 19857152
[TBL] [Abstract][Full Text] [Related]
9. Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.
Hartmann TN; Pleyer L; Desch P; Egle A; Greil R
Discov Med; 2009 Oct; 8(42):157-64. PubMed ID: 19833065
[TBL] [Abstract][Full Text] [Related]
10. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
11. Treatments for late-life bipolar disorder.
Aziz R; Lorberg B; Tampi RR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):347-64. PubMed ID: 17296540
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the treatment of B-cell chronic lymphocytic leukemia.
Cheson BD
Oncology (Williston Park); 1990 Sep; 4(9):71-8, 83-4; disc. 84, 87-8, 90 pass. PubMed ID: 2145022
[TBL] [Abstract][Full Text] [Related]
13. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.
Perkins JG; Flynn JM; Howard RS; Byrd JC
Cancer; 2002 Apr; 94(7):2033-9. PubMed ID: 11932906
[TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel.
Gridelli C; Aapro M; Ardizzoni A; Balducci L; De Marinis F; Kelly K; Le Chevalier T; Manegold C; Perrone F; Rosell R; Shepherd F; De Petris L; Di Maio M; Langer C
J Clin Oncol; 2005 May; 23(13):3125-37. PubMed ID: 15860872
[TBL] [Abstract][Full Text] [Related]
15. Pentostatin in chronic lymphocytic leukemia.
Sauter C; Lamanna N; Weiss MA
Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1217-22. PubMed ID: 18721115
[TBL] [Abstract][Full Text] [Related]
16. Signal transduction inhibitors in chronic lymphocytic leukemia.
Ma S; Rosen ST
Curr Opin Oncol; 2011 Nov; 23(6):601-8. PubMed ID: 21892084
[TBL] [Abstract][Full Text] [Related]
17. Optimal management of older patients with chronic lymphocytic leukemia: some facts and principles guiding therapeutic choices.
Tadmor T; Polliack A
Blood Rev; 2012 Jan; 26(1):15-23. PubMed ID: 21955980
[TBL] [Abstract][Full Text] [Related]
18. Clinical roundtable monograph. New alternatives in CLL therapy: managing adverse events.
Chanan-Khan A; Kipps T; Stilgenbauer S
Clin Adv Hematol Oncol; 2010 Aug; 8(8):suppl 1-15. PubMed ID: 21192630
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies in chronic lymphocytic leukemia.
Ferrajoli A; Faderl S; Keating MJ
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1231-8. PubMed ID: 17020457
[TBL] [Abstract][Full Text] [Related]
20. Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
Brugiatelli M; Bandini G; Barosi G; Lauria F; Liso V; Marchetti M; Mauro FR; Meloni G; Zinzani PL; Tura S; ; ;
Haematologica; 2006 Dec; 91(12):1662-73. PubMed ID: 17145603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
